Click here to get full coverage on Growth Investors: Industry Analysts Just Upgraded Their Immunome, Inc. (NASDAQ:IMNM) Revenue Forecasts By 73% - Yahoo Finance

Growth Investors: Industry Analysts Just Upgraded Their Immunome, Inc. (NASDAQ:IMNM) Revenue Forecasts By 73%  Yahoo Finance

Growth Investors: Industry Analysts Just Upgraded Their Immunome, Inc. (NASDAQ:IMNM) Revenue Forecasts By 73% - Yahoo Finance

Click here to get full coverage on Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates - Nasdaq

Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates  Nasdaq

Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates - Nasdaq

Click here to get full coverage on New Analyst Forecast: $IMNM Given $22.0 Price Target - Quiver Quantitative

New Analyst Forecast: $IMNM Given $22.0 Price Target  Quiver Quantitative

New Analyst Forecast: $IMNM Given $22.0 Price Target - Quiver Quantitative

Click here to get full coverage on Immunome: SpringWorks Buyout Informs The Potential Upside Here (NASDAQ:IMNM) - Seeking Alpha

Immunome: SpringWorks Buyout Informs The Potential Upside Here (NASDAQ:IMNM)  Seeking Alpha

Immunome: SpringWorks Buyout Informs The Potential Upside Here (NASDAQ:IMNM) - Seeking Alpha

Click here to get full coverage on Cardiac involvement and anti-striational antibodies in immune-mediated necrotizing myopathy - ScienceDirect.com

Cardiac involvement and anti-striational antibodies in immune-mediated necrotizing myopathy  ScienceDirect.com

Cardiac involvement and anti-striational antibodies in immune-mediated necrotizing myopathy - ScienceDirect.com

Click here to get full coverage on Immunome, Inc. (NASDAQ:IMNM) Revenue Estimates Upgraded by 73% - AInvest

Immunome, Inc. (NASDAQ:IMNM) Revenue Estimates Upgraded by 73%  AInvest

Immunome, Inc. (NASDAQ:IMNM) Revenue Estimates Upgraded by 73% - AInvest

Click here to get full coverage on Cancer Therapy Developer Immunome Set for TD Cowen and Goldman Sachs Healthcare Conferences - Stock Titan

Cancer Therapy Developer Immunome Set for TD Cowen and Goldman Sachs Healthcare Conferences  Stock Titan

Cancer Therapy Developer Immunome Set for TD Cowen and Goldman Sachs Healthcare Conferences - Stock Titan

Click here to get full coverage on JP Morgan Lowers Price Target for Immunome (IMNM) While Maintain - GuruFocus

JP Morgan Lowers Price Target for Immunome (IMNM) While Maintain  GuruFocus

JP Morgan Lowers Price Target for Immunome (IMNM) While Maintain - GuruFocus

Click here to get full coverage on Bullish Immunome Insiders Loaded Up On US$3.84m Of Stock - simplywall.st

Bullish Immunome Insiders Loaded Up On US$3.84m Of Stock  simplywall.st

Bullish Immunome Insiders Loaded Up On US$3.84m Of Stock - simplywall.st

Click here to get full coverage on Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock? - Yahoo Finance

Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock?  Yahoo Finance

Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock? - Yahoo Finance

Click here to get full coverage on $IMNM stock is up 14% today. Here's what we see in our data. - Quiver Quantitative

$IMNM stock is up 14% today. Here's what we see in our data.  Quiver Quantitative

$IMNM stock is up 14% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High? - Nasdaq

Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High?  Nasdaq

Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High? - Nasdaq

Click here to get full coverage on Immunome: Transformed Pipeline Offers Multiple Catalysts (NASDAQ:IMNM) - Seeking Alpha

Immunome: Transformed Pipeline Offers Multiple Catalysts (NASDAQ:IMNM)  Seeking Alpha

Immunome: Transformed Pipeline Offers Multiple Catalysts (NASDAQ:IMNM) - Seeking Alpha

Click here to get full coverage on Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet - Yahoo Finance

Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet  Yahoo Finance

Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet - Yahoo Finance

Click here to get full coverage on Insider Purchase: Director at $IMNM Buys 7,800 Shares - Nasdaq

Insider Purchase: Director at $IMNM Buys 7,800 Shares  Nasdaq

Insider Purchase: Director at $IMNM Buys 7,800 Shares - Nasdaq

Click here to get full coverage on All You Need to Know About Immunome (IMNM) Rating Upgrade to Buy - Yahoo Finance

All You Need to Know About Immunome (IMNM) Rating Upgrade to Buy  Yahoo Finance

All You Need to Know About Immunome (IMNM) Rating Upgrade to Buy - Yahoo Finance

Click here to get full coverage on Immunome, Inc. (IMNM) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Immunome, Inc. (IMNM) Reports Q4 Loss, Misses Revenue Estimates  Yahoo Finance

Immunome, Inc. (IMNM) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Click here to get full coverage on Immunome Secures Nearly $400M War Chest as Phase 3 Trial Hits Key Milestone - Stock Titan

Immunome Secures Nearly $400M War Chest as Phase 3 Trial Hits Key Milestone  Stock Titan

Immunome Secures Nearly $400M War Chest as Phase 3 Trial Hits Key Milestone - Stock Titan

Click here to get full coverage on Immunome Advances Phase 3 Cancer Drug Trial with $268M War Chest, Multiple Pipeline Milestones Ahead - Stock Titan

Immunome Advances Phase 3 Cancer Drug Trial with $268M War Chest, Multiple Pipeline Milestones Ahead  Stock Titan

Immunome Advances Phase 3 Cancer Drug Trial with $268M War Chest, Multiple Pipeline Milestones Ahead - Stock Titan

Click here to get full coverage on Immunome's Latest Growth Move: 5 Key Hires Secure Significant Equity Package - Stock Titan

Immunome's Latest Growth Move: 5 Key Hires Secure Significant Equity Package  Stock Titan

Immunome's Latest Growth Move: 5 Key Hires Secure Significant Equity Package - Stock Titan

Click here to get full coverage on Immunome Secures Massive $172.5M Capital Injection as Top Banks Rush to Join Offering - Stock Titan

Immunome Secures Massive $172.5M Capital Injection as Top Banks Rush to Join Offering  Stock Titan

Immunome Secures Massive $172.5M Capital Injection as Top Banks Rush to Join Offering - Stock Titan

Click here to get full coverage on Unraveling the Immunome Stock Surge: A Technical and Market Behavior Deep Dive - AInvest

Unraveling the Immunome Stock Surge: A Technical and Market Behavior Deep Dive  AInvest

Unraveling the Immunome Stock Surge: A Technical and Market Behavior Deep Dive - AInvest

Click here to get full coverage on Monday 3/31 Insider Buying Report: IMNM - Nasdaq

Monday 3/31 Insider Buying Report: IMNM  Nasdaq

Monday 3/31 Insider Buying Report: IMNM - Nasdaq

Click here to get full coverage on A Quick Look at Today's Ratings for Immunome(IMNM.US), With a Forecast Between $21 to $38 - 富途牛牛

A Quick Look at Today's Ratings for Immunome(IMNM.US), With a Forecast Between $21 to $38  富途牛牛

A Quick Look at Today's Ratings for Immunome(IMNM.US), With a Forecast Between $21 to $38 - 富途牛牛

Click here to get full coverage on Immunome Can Take The Fight To Competitors With Varegacestat (NASDAQ:IMNM) - Seeking Alpha

Immunome Can Take The Fight To Competitors With Varegacestat (NASDAQ:IMNM)  Seeking Alpha

Immunome Can Take The Fight To Competitors With Varegacestat (NASDAQ:IMNM) - Seeking Alpha

Click here to get full coverage on Wedbush Reaffirms Buy Rating on Immunome with $21 Target - AInvest

Wedbush Reaffirms Buy Rating on Immunome with $21 Target  AInvest

Wedbush Reaffirms Buy Rating on Immunome with $21 Target - AInvest

Click here to get full coverage on What catalysts could drive IMNM stock higher in 2025 - Invest confidently with real-time market updates - Jammu Links News

What catalysts could drive IMNM stock higher in 2025 - Invest confidently with real-time market updates  Jammu Links News

What catalysts could drive IMNM stock higher in 2025 - Invest confidently with real-time market updates - Jammu Links News

Click here to get full coverage on Immunome Reports Second Quarter 2025 Financial Results and Provi - GuruFocus

Immunome Reports Second Quarter 2025 Financial Results and Provi  GuruFocus

Immunome Reports Second Quarter 2025 Financial Results and Provi - GuruFocus

Click here to get full coverage on Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference - Business Wire

Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference  Business Wire

Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference - Business Wire

Click here to get full coverage on Immunome Q2 Earnings: Revenue $4.01M, Consensus $1.02M; Expects Cash to Fund Operations into 2027 - AInvest

Immunome Q2 Earnings: Revenue $4.01M, Consensus $1.02M; Expects Cash to Fund Operations into 2027  AInvest

Immunome Q2 Earnings: Revenue $4.01M, Consensus $1.02M; Expects Cash to Fund Operations into 2027 - AInvest

Click here to get full coverage on Immunome Grants Inducement Awards to New Employees Under Nasdaq Rules, Prices Stock Options at $10.59. - AInvest

Immunome Grants Inducement Awards to New Employees Under Nasdaq Rules, Prices Stock Options at $10.59.  AInvest

Immunome Grants Inducement Awards to New Employees Under Nasdaq Rules, Prices Stock Options at $10.59. - AInvest

Click here to get full coverage on 3 Small-Cap Stocks With Big Growth Potential - MarketBeat

3 Small-Cap Stocks With Big Growth Potential  MarketBeat

3 Small-Cap Stocks With Big Growth Potential - MarketBeat

Click here to get full coverage on Immunome's SpringWorks Buyout Highlights Upside Potential - AInvest

Immunome's SpringWorks Buyout Highlights Upside Potential  AInvest

Immunome's SpringWorks Buyout Highlights Upside Potential - AInvest

Click here to get full coverage on Immunome Announces Pricing of Upsized Public Offering of Common Stock - Business Wire

Immunome Announces Pricing of Upsized Public Offering of Common Stock  Business Wire

Immunome Announces Pricing of Upsized Public Offering of Common Stock - Business Wire

Click here to get full coverage on Trading (IMNM) With Integrated Risk Controls - news.stocktradersdaily.com

Trading (IMNM) With Integrated Risk Controls  news.stocktradersdaily.com

Trading (IMNM) With Integrated Risk Controls - news.stocktradersdaily.com

Click here to get full coverage on Is IMNM a growth stock or a value stock - Build a strong portfolio for growth and safety - Jammu Links News

Is IMNM a growth stock or a value stock - Build a strong portfolio for growth and safety  Jammu Links News

Is IMNM a growth stock or a value stock - Build a strong portfolio for growth and safety - Jammu Links News

Click here to get full coverage on When ALOT stock expected to show significant growthIs IMNM stock a good long term investment option - Verified Signal From Chart Patterns Detected - beatles.ru

When ALOT stock expected to show significant growthIs IMNM stock a good long term investment option - Verified Signal From Chart Patterns Detected  beatles.ru

When ALOT stock expected to show significant growthIs IMNM stock a good long term investment option - Verified Signal From Chart Patterns Detected - beatles.ru

Click here to get full coverage on Immunome: A Recently Acquired Lead Asset And A Small Market (NASDAQ:IMNM) - Seeking Alpha

Immunome: A Recently Acquired Lead Asset And A Small Market (NASDAQ:IMNM)  Seeking Alpha

Immunome: A Recently Acquired Lead Asset And A Small Market (NASDAQ:IMNM) - Seeking Alpha

Click here to get full coverage on Can IMNM disrupt its industry - Market Sentiment Review & Long-Term Safe Investment Ideas - mustnews.co.kr

Can IMNM disrupt its industry - Market Sentiment Review & Long-Term Safe Investment Ideas  mustnews.co.kr

Can IMNM disrupt its industry - Market Sentiment Review & Long-Term Safe Investment Ideas - mustnews.co.kr

Click here to get full coverage on Voyager Therapeutics: Wedbush Downgrades to Outperform, PT to $8 from $9 - AInvest

Voyager Therapeutics: Wedbush Downgrades to Outperform, PT to $8 from $9  AInvest

Voyager Therapeutics: Wedbush Downgrades to Outperform, PT to $8 from $9 - AInvest

Click here to get full coverage on Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire

Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update  Business Wire

Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire

Click here to get full coverage on How volatile is IMNM stock compared to the market - Invest smarter with daily market updates - Jammu Links News

How volatile is IMNM stock compared to the market - Invest smarter with daily market updates  Jammu Links News

How volatile is IMNM stock compared to the market - Invest smarter with daily market updates - Jammu Links News

Click here to get full coverage on Immunome Provides Pipeline Update in Advance of Presentation at the 43 - Business Wire

Immunome Provides Pipeline Update in Advance of Presentation at the 43  Business Wire

Immunome Provides Pipeline Update in Advance of Presentation at the 43 - Business Wire

Click here to get full coverage on Ichimoku Cloud Indicates Uncertainty Around IMNM - Risk Controlled Picks With Real Returns Outlined - metal.it

Ichimoku Cloud Indicates Uncertainty Around IMNM - Risk Controlled Picks With Real Returns Outlined  metal.it

Ichimoku Cloud Indicates Uncertainty Around IMNM - Risk Controlled Picks With Real Returns Outlined - metal.it

Click here to get full coverage on Immunome Reports First Quarter 2025 Financial Results and Provides Business Update - Business Wire

Immunome Reports First Quarter 2025 Financial Results and Provides Business Update  Business Wire

Immunome Reports First Quarter 2025 Financial Results and Provides Business Update - Business Wire

Click here to get full coverage on Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC - Business Wire

Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC  Business Wire

Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC - Business Wire

Click here to get full coverage on When ALOT stock expected to show significant growthIs IMNM stock a good long term investment option - Breakout Level Watch - metal.it

When ALOT stock expected to show significant growthIs IMNM stock a good long term investment option - Breakout Level Watch  metal.it

When ALOT stock expected to show significant growthIs IMNM stock a good long term investment option - Breakout Level Watch - metal.it

Click here to get full coverage on When IMNM stock expected to show significant growthIs DRTSW stock a good long term investment option - Best Stocks for Capital Safety - metal.it

When IMNM stock expected to show significant growthIs DRTSW stock a good long term investment option - Best Stocks for Capital Safety  metal.it

When IMNM stock expected to show significant growthIs DRTSW stock a good long term investment option - Best Stocks for Capital Safety - metal.it

Click here to get full coverage on argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies - GlobeNewswire

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies  GlobeNewswire

argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies - GlobeNewswire

Click here to get full coverage on Immunome (NASDAQ:IMNM): An Opportunity for Investors with Strong Stomachs - Nasdaq

Immunome (NASDAQ:IMNM): An Opportunity for Investors with Strong Stomachs  Nasdaq

Immunome (NASDAQ:IMNM): An Opportunity for Investors with Strong Stomachs - Nasdaq

Click here to get full coverage on Immunome: An Oncology Powerhouse In The Making (NASDAQ:IMNM) - Seeking Alpha

Immunome: An Oncology Powerhouse In The Making (NASDAQ:IMNM)  Seeking Alpha

Immunome: An Oncology Powerhouse In The Making (NASDAQ:IMNM) - Seeking Alpha

Click here to get full coverage on Clinical and pathological features of immune-mediated necrotising myopathies in a single-centre muscle biopsy cohort - BMC Musculoskeletal Disorders

Clinical and pathological features of immune-mediated necrotising myopathies in a single-centre muscle biopsy cohort  BMC Musculoskeletal Disorders

Clinical and pathological features of immune-mediated necrotising myopathies in a single-centre muscle biopsy cohort - BMC Musculoskeletal Disorders

Click here to get full coverage on Interstitial lung disease is not rare in immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies - BMC Pulmonary Medicine

Interstitial lung disease is not rare in immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies  BMC Pulmonary Medicine

Interstitial lung disease is not rare in immune-mediated necrotizing myopathy with anti-signal recognition particle antibodies - BMC Pulmonary Medicine

Click here to get full coverage on Identification of feature genes and key biological pathways in immune-mediated necrotizing myopathy: High-throughput sequencing and bioinformatics analysis - ScienceDirect.com

Identification of feature genes and key biological pathways in immune-mediated necrotizing myopathy: High-throughput sequencing and bioinformatics analysis  ScienceDirect.com

Identification of feature genes and key biological pathways in immune-mediated necrotizing myopathy: High-throughput sequencing and bioinformatics analysis - ScienceDirect.com

Click here to get full coverage on Belimumab for Immune-Mediated Necrotizing Myopathy Associated With Anti-SRP Antibodies: A Case Report and Retrospective Review of Patients Treated With Anti-B-Cell Therapy in a Single Center and Literature - Frontiers

Belimumab for Immune-Mediated Necrotizing Myopathy Associated With Anti-SRP Antibodies: A Case Report and Retrospective Review of Patients Treated With Anti-B-Cell Therapy in a Single Center and Literature  Frontiers

Belimumab for Immune-Mediated Necrotizing Myopathy Associated With Anti-SRP Antibodies: A Case Report and Retrospective Review of Patients Treated With Anti-B-Cell Therapy in a Single Center and Literature - Frontiers

Click here to get full coverage on IMNM Stock Earnings: Immunome Beats EPS, Beats Revenue for Q4 2023 - TradingView

IMNM Stock Earnings: Immunome Beats EPS, Beats Revenue for Q4 2023  TradingView

IMNM Stock Earnings: Immunome Beats EPS, Beats Revenue for Q4 2023 - TradingView

Click here to get full coverage on Serum cytokine and chemokine profiles in patients with immune-mediated necrotizing myopathy - ScienceDirect.com

Serum cytokine and chemokine profiles in patients with immune-mediated necrotizing myopathy  ScienceDirect.com

Serum cytokine and chemokine profiles in patients with immune-mediated necrotizing myopathy - ScienceDirect.com

Click here to get full coverage on Insider Buying: Immunome Inc's CEO Acquires 100,000 Shares - Yahoo Finance

Insider Buying: Immunome Inc's CEO Acquires 100,000 Shares  Yahoo Finance

Insider Buying: Immunome Inc's CEO Acquires 100,000 Shares - Yahoo Finance

Click here to get full coverage on Pathophysiology of IMNM. IMNM pathophysiology combines innate risk (HLA... - researchgate.net

Pathophysiology of IMNM. IMNM pathophysiology combines innate risk (HLA...  researchgate.net

Pathophysiology of IMNM. IMNM pathophysiology combines innate risk (HLA... - researchgate.net

Click here to get full coverage on The Clinicopathological Distinction Between Seropositive and Seronegative Immune-Mediated Necrotizing Myopathy in China - Frontiers

The Clinicopathological Distinction Between Seropositive and Seronegative Immune-Mediated Necrotizing Myopathy in China  Frontiers

The Clinicopathological Distinction Between Seropositive and Seronegative Immune-Mediated Necrotizing Myopathy in China - Frontiers

Click here to get full coverage on Anti-signal recognition particle positive necrotizing myopathy-sjogren’s syndrome overlap syndrome: a descriptive study on clinical and myopathology features - BMC Musculoskeletal Disorders

Anti-signal recognition particle positive necrotizing myopathy-sjogren’s syndrome overlap syndrome: a descriptive study on clinical and myopathology features  BMC Musculoskeletal Disorders

Anti-signal recognition particle positive necrotizing myopathy-sjogren’s syndrome overlap syndrome: a descriptive study on clinical and myopathology features - BMC Musculoskeletal Disorders

Click here to get full coverage on Proposed mechanisms of miR-18a-3p and its target HuR in the IMNM... - researchgate.net

Proposed mechanisms of miR-18a-3p and its target HuR in the IMNM...  researchgate.net

Proposed mechanisms of miR-18a-3p and its target HuR in the IMNM... - researchgate.net

Click here to get full coverage on Myositis Extended Panel for Case 2 - researchgate.net

Myositis Extended Panel for Case 2  researchgate.net

Myositis Extended Panel for Case 2 - researchgate.net

Click here to get full coverage on Immunome (IMNM) Stock Price, News & Analysis - MarketBeat

Immunome (IMNM) Stock Price, News & Analysis  MarketBeat

Immunome (IMNM) Stock Price, News & Analysis - MarketBeat

Click here to get full coverage on BCMA CAR T therapy facilitates potential autoimmune breakthrough - European Pharmaceutical Review

BCMA CAR T therapy facilitates potential autoimmune breakthrough  European Pharmaceutical Review

BCMA CAR T therapy facilitates potential autoimmune breakthrough - European Pharmaceutical Review

Click here to get full coverage on IVIg Shows 85% Response Rate in IMNM Patients - Physician's Weekly

IVIg Shows 85% Response Rate in IMNM Patients  Physician's Weekly

IVIg Shows 85% Response Rate in IMNM Patients - Physician's Weekly

Click here to get full coverage on Immunome Announces Completion of Purchase of Assets from Atreca - Business Wire

Immunome Announces Completion of Purchase of Assets from Atreca  Business Wire

Immunome Inc (IMNM)

Price Chart

Key Statistics

Technicals

About IMNM

Latest News

Growth Investors: Industry Analysts Just Upgraded Their Immunome, Inc. (NASDAQ:IMNM) Revenue Forecasts By 73% - Yahoo Finance

Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates - Nasdaq

New Analyst Forecast: $IMNM Given $22.0 Price Target - Quiver Quantitative

Advanced Charts

Top Gainers

Top Losers